Our regenerative technology is breaking the frontier in therapeutic and cosmetic applications.
Reinventing The Way Forward
At Celligenics, we are reinventing the way forward by discovering and developing therapies, and harnessing regenerative technology, to support the body in repairing, regenerating, and restoring itself to a state of well-being.
A unique sub-population of stem cells that embody the best qualities of embryonic and adult set cells without theirdown sides.
Proprietary Process that extracts stem cells at a purity level of more than 90%, resulting in superior regenerative qualities.
By only using the secretions instead of the stem cells, the regenerative extract is cell-free, which reduces safety and ethical issues.
Utilising the regenerative extract, with our optimised proprietary processes, allows greater scalability and cost-effectiveness.
Our core technology is CEL1, a regenerative extract that harnesses stem cell secretions to
stimulate cell repair and regeneration.
Our regenerative extract is a platform technology, with limitless application potential. Two product lines are currently under development, with more to come.
Chronic ulcers are wounds that affect old, sick, or obese people with poor blood circulation. They do not heal on their own, and, even with treatment, the average chronic ulcer takes at least 3 months to heal.
Our regenerative extract, formulated with optimised stem cell secretions, can double the rate of wound healing, and as a result, shorten and reduce hospitalisation incidence, and lower treatment costs for patients.
Ready For Phase 1 Clinical Trials 
Traditional skincare products inevitably lose their effectiveness over time, and stronger and more expensive products are then required to maintain the health of our skin.
From our regenerative extract, we have derived a skincare blend that contains biologically active ingredients that do not just make your skin look better temporarily, but actually create lasting changes in your skin.
Ready For Launch [H2 2023]
Established in 2016, Celligenics is a spin-off of the Agency for Science, Technology & Research (A*STAR), Singapore’s lead public research & development agency, and one of A*STAR’s top 10 new
biotechnology start-ups in 2018.
We are also a finalist for Singapore’s Emerging Enterprise Award 2021, the top business award jointly organised by OCBC Bank and The Business times that recognises the ambitions of emerging enterprises.
A Singapore Biotechnology Company
The People At Celligenics
Collectively, our core expertise spans across investment finance, enterprise strategy and product development, as well as experience in the field of working with molecular and cell biology.
KOH Choon Hui
Prof. David BECKER
Dr. Pamela MOK
Scientific Director, Regenerative Technology
Founder & CEO
Prof. Prabha SAMPATH
Head, Corporate Development
HUANG Ban Chin
Prof. Amittha WICKREMA
We leverage the strength of our strategic partnerships to accelerate innovative growth, find new audiences, and optimise our value chain.
We strive to create impact where it matters. Here are some of our media mentions and latest updates.